Kazia Therapeutics Limited stock is up 25.28% since 30 days ago. The next earnings date is Sep 26, 2023. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 48% of the previous 24 November’s closed higher than October.
Kazia Therapeutics Limited is an oncology-focused biotechnology company. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway. It is also developing EVT801, an investigational new drug for various forms of cancer.